Every 10-Q that Nektar Therapeutics (NKTR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NKTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTR filings page.
Nektar Therapeutics reported a first-half 2026 net loss of $85.5 million, modestly improved from $92.5 million a year earlier, on $21.0 million of non-cash royalty revenue. Operating expenses were $102.4 million, driven mainly by increased research and development spending on rezpegaldesleukin and TNFR2 programs.
Liquidity strengthened significantly: cash and investments in marketable securities totaled $1.02 billion at June 30, 2026, up from $245.8 million at year-end, largely from equity offerings that raised $1.07 billion in net proceeds between July 2025 and April 2026. The company states it has sufficient capital to fund operations for at least 12 months.
Nektar remains a clinical-stage immunology company focused on rezpegaldesleukin in atopic dermatitis, alopecia areata and Type 1 diabetes, with Phase 3 ZENITH AD trials recently initiated and Phase 2b REZOLVE-AD and REZOLVE-AA trials ongoing. The business continues to incur substantial losses and expects significant ongoing R&D investment.
Nektar Therapeutics reported a first-quarter 2026 net loss of $44.9 million on total revenue of $10.9 million, all from non-cash royalty revenue tied to previously sold royalty streams. Operating expenses were $49.9 million, driven mainly by research and development spending.
The company’s cash and investments in marketable securities rose sharply to $731.6 million as of March 31, 2026, supported by recent equity offerings and at-the-market sales that generated net proceeds of $1.07 billion between July 2025 and April 2026. Shares of common stock outstanding were 33,786,032 on May 1, 2026.
Nektar Therapeutics filed its Q3 2025 10‑Q, reporting continued operating losses alongside a strengthened cash position. Total revenue was $11.8 million, primarily from non‑cash royalty revenue related to prior royalty sales, down from $24.1 million a year ago. The company reported a net loss of $35.5 million for the quarter and $128.0 million year‑to‑date.
Cash, cash equivalents and marketable securities totaled $270.2 million as of September 30, 2025. During the quarter, Nektar completed an underwritten public offering of 4,893,618 shares at $23.50 per share for approximately $107.2 million in net proceeds, issued 600,198 shares under its at‑the‑market program for $34.3 million in net proceeds, and saw exercise of a 1,666,667‑share pre‑funded warrant. A one‑for‑fifteen reverse stock split became effective on June 8, 2025.
Following the December 2024 sale of its Huntsville manufacturing facility, Nektar no longer records product sales and recognized a $0 product sales line this quarter. The company continues Phase 2b programs for rezpegaldesleukin and recorded a small loss from its equity method investment in Gannet BioChem.